Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152008 | 0.93 | L3MBTL1 (0.35) | CYP1A2CYP3A4CYP2C9L3MBTL1CYP2D6 | |
| SCHEMBL18386083 | 0.92 | L3MBTL1 (0.37) | POLBL3MBTL1MAPK1HSD17B10KDM4E | |
| SCHEMBL17152017 | 0.88 | RARA (0.34) | CYP1A2CYP3A4NR1I3CYP2C9CYP2B6 | |
| SCHEMBL18386089 | 0.88 | ENPP1 (0.32) | L3MBTL1MAPK1HSD17B10KDM4ETP53 | |
| SCHEMBL17152055 | 0.88 | CYP1A2 (0.33) | CYP1A2CYP3A4NR1I3CYP2C9CYP2B6 | |
| SCHEMBL18463332 | 0.87 | GP6 (0.36) | RARARARBRARGGP6L3MBTL1 | |
| SCHEMBL26937484 | 0.87 | GP6 (0.36) | RARARARBRARGGP6L3MBTL1 | |
| SCHEMBL18463318 | 0.87 | GP6 (0.36) | RARARARBRARGGP6L3MBTL1 | |
| SCHEMBL19754714 | 0.87 | NR1I3 (0.31) | CYP1A2CYP3A4NR1I3CYP2C9CYP2B6 | |
| SCHEMBL17152061 | 0.86 | CYP1A2 (0.32) | CYP1A2CYP3A4NR1I3CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024114-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-10381572-B2 | Heterocyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2019-08-13 | — | — | US | disclosed |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-01-19 | — | — | US | disclosed |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-01-19 | — | — | US | disclosed |
| WO-2015152651-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10381572-B2 | Heterocyclic compound and organic light-emitting element comprising same | CRY1, CRY2, PER2 | CYP1A2 202/4885CYP3A4 84/4885NR1I3 416/4885 |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | CYP1A2 202/4885CYP3A4 84/4885NR1I3 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.